Form 4: Pfizer Director James C. Smith Reports Acquisition of Phantom Stock Units
SEC Form 4 Filing
Director James C. Smith reports acquisition of phantom stock units representing deferred director's compensation.
Summary
- On June 28, 2024, James C. Smith, a director of Pfizer Inc., acquired 1,608.292 phantom stock units.
- These units represent deferred director's compensation, including dividend equivalents.
- The units will be settled in cash or common stock at the director's election following retirement from the Board of Directors.
- The price of the underlying common stock was $27.98.
- Following the transaction, Smith beneficially owns 132,125.258 phantom stock units.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, neither inherently positive nor negative.
Future Outlook
The phantom stock units will be settled in cash or common stock at the director's election following retirement from the Board of Directors.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding director compensation.
Key Dates
| Date | Description |
|---|---|
| 06/28/2024 | Date of transaction: Acquisition of phantom stock units |
| 07/01/2024 | Date of signature on the report |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.